Under the revised agreement, Merck gains expanded access to Adimab’s technology for the discovery and optimization of fully human antibody candidates.
Adimab will develop therapeutic antibody candidates against several targets nominated by Merck for three years.
Merck Research Laboratories biologics discovery vice president Deborah Law said, "At Merck, we look at a lot of technologies and have been impressed with Adimab’s output in our previous collaboration."
According to the other expanded agreement, Adimab will discover and optimize several bispecific antibodies against Lilly nominated molecular targets.
Adimab CEO and co-founder Tillman Gerngross said, "The antibody discovery arena has become very competitive and nothing is more validating than existing partners coming back for broader access to our platform."
As a part of the contracts, Adimab will earn upfront payments, preclinical and clinical development milestone payments in addition to sales based royalties.